Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Werte in diesem Artikel
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.The Style Scores are broken down into four categories:Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.That's where the Style Scores come in.You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: BioMarin Pharmaceutical (BMRN) San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children.BMRN is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.75; value investors should take notice.Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.01 to $3.29 per share. BMRN boasts an average earnings surprise of 28.7%.With a solid Zacks Rank and top-tier Value and VGM Style Scores, BMRN should be on investors' short list.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.1% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Biomarin Pharmaceutical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Biomarin Pharmaceutical
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Biomarin Pharmaceutical Inc.
Analysen zu Biomarin Pharmaceutical Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
01.10.2018 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
07.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
03.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
16.05.2018 | Biomarin Pharmaceutical Buy | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
01.10.2018 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
07.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
03.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
16.05.2018 | Biomarin Pharmaceutical Buy | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | Biomarin Pharmaceutical Sector Perform | RBC Capital Markets | |
30.03.2017 | Biomarin Pharmaceutical Neutral | UBS AG | |
02.03.2017 | Biomarin Pharmaceutical Neutral | Instinet | |
29.02.2016 | Biomarin Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
25.11.2015 | Biomarin Pharmaceutical Perform | Oppenheimer & Co. Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biomarin Pharmaceutical Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen